- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
These antibodies are used to treat metastatic (spread) breast cancer. It is effective against tumors that overexpress the HER2/neu protein.
According to our latest study, the global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market size and forecasts, in consumption value ($ Million), 2018-2029
Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, BOC Sciences, LGM Pharma, Biotechnica Pharma Global and KinBio and etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Pertuzumab
Trastuzumab
Market segment by Application
Combination Therapy
Mono Therapy
Market segment by players, this report covers
Roche
BOC Sciences
LGM Pharma
Biotechnica Pharma Global
KinBio
Merck
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer, with revenue, gross margin and global market share of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer from 2018 to 2023.
Chapter 3, the Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer.
Chapter 13, to describe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer research findings and conclusion.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer by Type
1.3.1 Overview: Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Market Share by Type in 2022
1.3.3 Pertuzumab
1.3.4 Trastuzumab
1.4 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market by Application
1.4.1 Overview: Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Combination Therapy
1.4.3 Mono Therapy
1.5 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size & Forecast
1.6 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast by Region
1.6.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Region, (2018-2029)
1.6.3 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Prospect (2018-2029)
1.6.4 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Prospect (2018-2029)
1.6.6 South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product and Solutions
2.1.4 Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Roche Recent Developments and Future Plans
2.2 BOC Sciences
2.2.1 BOC Sciences Details
2.2.2 BOC Sciences Major Business
2.2.3 BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product and Solutions
2.2.4 BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 BOC Sciences Recent Developments and Future Plans
2.3 LGM Pharma
2.3.1 LGM Pharma Details
2.3.2 LGM Pharma Major Business
2.3.3 LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product and Solutions
2.3.4 LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 LGM Pharma Recent Developments and Future Plans
2.4 Biotechnica Pharma Global
2.4.1 Biotechnica Pharma Global Details
2.4.2 Biotechnica Pharma Global Major Business
2.4.3 Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product and Solutions
2.4.4 Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Biotechnica Pharma Global Recent Developments and Future Plans
2.5 KinBio
2.5.1 KinBio Details
2.5.2 KinBio Major Business
2.5.3 KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product and Solutions
2.5.4 KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 KinBio Recent Developments and Future Plans
2.6 Merck
2.6.1 Merck Details
2.6.2 Merck Major Business
2.6.3 Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product and Solutions
2.6.4 Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Merck Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer by Company Revenue
3.2.2 Top 3 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Players Market Share in 2022
3.2.3 Top 6 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Players Market Share in 2022
3.3 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market: Overall Company Footprint Analysis
3.3.1 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market: Region Footprint
3.3.2 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market: Company Product Type Footprint
3.3.3 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value and Market Share by Type (2018-2023)
4.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Market Share by Application (2018-2023)
5.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Forecast by Application (2024-2029)
6 North America
6.1 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Type (2018-2029)
6.2 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Application (2018-2029)
6.3 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country
6.3.1 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Country (2018-2029)
6.3.2 United States Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2018-2029)
6.3.3 Canada Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2018-2029)
6.3.4 Mexico Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Type (2018-2029)
7.2 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Application (2018-2029)
7.3 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country
7.3.1 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Country (2018-2029)
7.3.2 Germany Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2018-2029)
7.3.3 France Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2018-2029)
7.3.5 Russia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2018-2029)
7.3.6 Italy Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Region
8.3.1 Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Region (2018-2029)
8.3.2 China Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2018-2029)
8.3.3 Japan Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2018-2029)
8.3.4 South Korea Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2018-2029)
8.3.5 India Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2018-2029)
8.3.7 Australia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2018-2029)
9 South America
9.1 South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Type (2018-2029)
9.2 South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Application (2018-2029)
9.3 South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country
9.3.1 South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Country (2018-2029)
9.3.2 Brazil Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2018-2029)
9.3.3 Argentina Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country
10.3.1 Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Country (2018-2029)
10.3.2 Turkey Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2018-2029)
10.3.4 UAE Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Drivers
11.2 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Restraints
11.3 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Industry Chain
12.2 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Upstream Analysis
12.3 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Midstream Analysis
12.4 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Roche Company Information, Head Office, and Major Competitors
Table 6. Roche Major Business
Table 7. Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product and Solutions
Table 8. Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Roche Recent Developments and Future Plans
Table 10. BOC Sciences Company Information, Head Office, and Major Competitors
Table 11. BOC Sciences Major Business
Table 12. BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product and Solutions
Table 13. BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. BOC Sciences Recent Developments and Future Plans
Table 15. LGM Pharma Company Information, Head Office, and Major Competitors
Table 16. LGM Pharma Major Business
Table 17. LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product and Solutions
Table 18. LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. LGM Pharma Recent Developments and Future Plans
Table 20. Biotechnica Pharma Global Company Information, Head Office, and Major Competitors
Table 21. Biotechnica Pharma Global Major Business
Table 22. Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product and Solutions
Table 23. Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Biotechnica Pharma Global Recent Developments and Future Plans
Table 25. KinBio Company Information, Head Office, and Major Competitors
Table 26. KinBio Major Business
Table 27. KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product and Solutions
Table 28. KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. KinBio Recent Developments and Future Plans
Table 30. Merck Company Information, Head Office, and Major Competitors
Table 31. Merck Major Business
Table 32. Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product and Solutions
Table 33. Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Merck Recent Developments and Future Plans
Table 35. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue (USD Million) by Players (2018-2023)
Table 36. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Share by Players (2018-2023)
Table 37. Breakdown of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer by Company Type (Tier 1, Tier 2, and Tier 3)
Table 38. Market Position of Players in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 39. Head Office of Key Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Players
Table 40. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market: Company Product Type Footprint
Table 41. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market: Company Product Application Footprint
Table 42. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer New Market Entrants and Barriers to Market Entry
Table 43. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Mergers, Acquisition, Agreements, and Collaborations
Table 44. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (USD Million) by Type (2018-2023)
Table 45. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Share by Type (2018-2023)
Table 46. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Forecast by Type (2024-2029)
Table 47. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Application (2018-2023)
Table 48. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Forecast by Application (2024-2029)
Table 49. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Type (2018-2023) & (USD Million)
Table 50. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Type (2024-2029) & (USD Million)
Table 51. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Application (2018-2023) & (USD Million)
Table 52. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Application (2024-2029) & (USD Million)
Table 53. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Country (2018-2023) & (USD Million)
Table 54. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Country (2024-2029) & (USD Million)
Table 55. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Type (2018-2023) & (USD Million)
Table 56. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Type (2024-2029) & (USD Million)
Table 57. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Application (2018-2023) & (USD Million)
Table 58. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Application (2024-2029) & (USD Million)
Table 59. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Country (2018-2023) & (USD Million)
Table 60. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Country (2024-2029) & (USD Million)
Table 61. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Type (2018-2023) & (USD Million)
Table 62. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Type (2024-2029) & (USD Million)
Table 63. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Application (2018-2023) & (USD Million)
Table 64. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Application (2024-2029) & (USD Million)
Table 65. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Region (2018-2023) & (USD Million)
Table 66. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Region (2024-2029) & (USD Million)
Table 67. South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Type (2018-2023) & (USD Million)
Table 68. South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Type (2024-2029) & (USD Million)
Table 69. South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Application (2018-2023) & (USD Million)
Table 70. South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Application (2024-2029) & (USD Million)
Table 71. South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Country (2018-2023) & (USD Million)
Table 72. South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Country (2024-2029) & (USD Million)
Table 73. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Type (2018-2023) & (USD Million)
Table 74. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Type (2024-2029) & (USD Million)
Table 75. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Application (2018-2023) & (USD Million)
Table 76. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Application (2024-2029) & (USD Million)
Table 77. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Country (2018-2023) & (USD Million)
Table 78. Middle East & Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Country (2024-2029) & (USD Million)
Table 79. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Raw Material
Table 80. Key Suppliers of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Raw Materials
List of Figures
Figure 1. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Picture
Figure 2. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Market Share by Type in 2022
Figure 4. Pertuzumab
Figure 5. Trastuzumab
Figure 6. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Market Share by Application in 2022
Figure 8. Combination Therapy Picture
Figure 9. Mono Therapy Picture
Figure 10. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 11. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 12. Global Market Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 13. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Market Share by Region (2018-2029)
Figure 14. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Market Share by Region in 2022
Figure 15. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (2018-2029) & (USD Million)
Figure 16. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (2018-2029) & (USD Million)
Figure 17. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (2018-2029) & (USD Million)
Figure 18. South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (2018-2029) & (USD Million)
Figure 19. Middle East and Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (2018-2029) & (USD Million)
Figure 20. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Share by Players in 2022
Figure 21. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 22. Global Top 3 Players Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share in 2022
Figure 23. Global Top 6 Players Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share in 2022
Figure 24. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Share by Type (2018-2023)
Figure 25. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share Forecast by Type (2024-2029)
Figure 26. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Share by Application (2018-2023)
Figure 27. Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share Forecast by Application (2024-2029)
Figure 28. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Market Share by Type (2018-2029)
Figure 29. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Market Share by Application (2018-2029)
Figure 30. North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Market Share by Country (2018-2029)
Figure 31. United States Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (2018-2029) & (USD Million)
Figure 32. Canada Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (2018-2029) & (USD Million)
Figure 33. Mexico Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (2018-2029) & (USD Million)
Figure 34. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Market Share by Type (2018-2029)
Figure 35. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Market Share by Application (2018-2029)
Figure 36. Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Market Share by Country (2018-2029)
Figure 37. Germany Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (2018-2029) & (USD Million)
Figure 38. France Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (2018-2029) & (USD Million)
Figure 39. United Kingdom Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (2018-2029) & (USD Million)
Figure 40. Russia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (2018-2029) & (USD Million)
Figure 41. Italy Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (2018-2029) & (USD Million)
Figure 42. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Market Share by Type (2018-2029)
Figure 43. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Market Share by Application (2018-2029)
Figure 44. Asia-Pacific Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Market Share by Region (2018-2029)
Figure 45. China Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (2018-2029) & (USD Million)
Figure 46. Japan Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (2018-2029) & (USD Million)
Figure 47. South Korea Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (2018-2029) & (USD Million)
Figure 48. India Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (2018-2029) & (USD Million)
Figure 49. Southeast Asia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (2018-2029) & (USD Million)
Figure 50. Australia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (2018-2029) & (USD Million)
Figure 51. South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Market Share by Type (2018-2029)
Figure 52. South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Market Share by Application (2018-2029)
Figure 53. South America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Market Share by Country (2018-2029)
Figure 54. Brazil Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (2018-2029) & (USD Million)
Figure 55. Argentina Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (2018-2029) & (USD Million)
Figure 56. Middle East and Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Market Share by Type (2018-2029)
Figure 57. Middle East and Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Market Share by Application (2018-2029)
Figure 58. Middle East and Africa Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value Market Share by Country (2018-2029)
Figure 59. Turkey Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (2018-2029) & (USD Million)
Figure 60. Saudi Arabia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (2018-2029) & (USD Million)
Figure 61. UAE Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Consumption Value (2018-2029) & (USD Million)
Figure 62. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Drivers
Figure 63. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Restraints
Figure 64. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Trends
Figure 65. Porters Five Forces Analysis
Figure 66. Manufacturing Cost Structure Analysis of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer in 2022
Figure 67. Manufacturing Process Analysis of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer
Figure 68. Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Industrial Chain
Figure 69. Methodology
Figure 70. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
